Javascript must be enabled to continue!
1038 Outcomes of Non-Alcoholic Steatohepatitis in African American Patients With Human Immunodeficiency Virus (HIV)
View through CrossRef
INTRODUCTION:
Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome and is highly prevalent in patients with HIV, ranging from 13% to 55%. According to the center for disease control and prevention (CDC), in 2016 African Americans(AA) had the highest rate of HIV diagnosis (44%).Minorities are disproportionately affected by HIV and have a higher risk of developing NASH and progressive liver disease. Data on the outcomes of NASH in AA patients with HIV and the disease progression is scanty and poorly studied.
METHODS:
We retrieved data from the Nationwide Inpatient Sample (NIS) database for the year 2012.The study group consisted of AA patients between ages 18–75 years with NASH and HIV/AIDS (n = 138). Control group included subjects with NASH alone (n = 3681). Our outcomes of interest were: overall mortality, Ascites, Hepatocellular carcinoma (HCC), End stage liver disease (ESLD), Hepatic encephalopathy (HE), Liver cirrhosis and Portal hypertension. All clinical characteristics were defined as per the International Classification of Disease 9th revision (ICD-9) codes. Logistics regression analysis was used to estimate the adjusted odds ratio (aOR) of outcomes amongst participants with coexisting NASH/HIV while accounting for comorbidities and this was compared to those with NASH alone.
RESULTS:
The mean age sample was 49 ± 12 (61% female, 39% male). The rates of ascites were higher among those with NASH/HIV compared to NASH alone (10.1% vs 4.6%, P < 0.005). After adjusting for comorbidities, the aOR for hepatic encephalopathy 1.232 (0.379-4.009), ascites 1.753 (0.962-3.196) and portal hypertension 2.258 (0.276-18.465) was higher in NASH/HIV group compared to NASH alone. Stratified analysis based on age and sex revealed that females with NASH/HIV have a statistically significant higher odd for ascites; age 18-45, aoR 4.752 (2.155-10.478) and portal hypertension age 46- 75 aoR 19.832 (1.182 - 332.644) compared with NASH alone.
CONCLUSION:
African American female patients with NASH coexisting with HIV were at a higher risk for portal hypertension and ascites when compared to those with NASH alone. Further studies will look to evaluate and mitigate the impact of HIV on NASH in this patient population.
Ovid Technologies (Wolters Kluwer Health)
Title: 1038 Outcomes of Non-Alcoholic Steatohepatitis in African American Patients With Human Immunodeficiency Virus (HIV)
Description:
INTRODUCTION:
Non-alcoholic steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome and is highly prevalent in patients with HIV, ranging from 13% to 55%.
According to the center for disease control and prevention (CDC), in 2016 African Americans(AA) had the highest rate of HIV diagnosis (44%).
Minorities are disproportionately affected by HIV and have a higher risk of developing NASH and progressive liver disease.
Data on the outcomes of NASH in AA patients with HIV and the disease progression is scanty and poorly studied.
METHODS:
We retrieved data from the Nationwide Inpatient Sample (NIS) database for the year 2012.
The study group consisted of AA patients between ages 18–75 years with NASH and HIV/AIDS (n = 138).
Control group included subjects with NASH alone (n = 3681).
Our outcomes of interest were: overall mortality, Ascites, Hepatocellular carcinoma (HCC), End stage liver disease (ESLD), Hepatic encephalopathy (HE), Liver cirrhosis and Portal hypertension.
All clinical characteristics were defined as per the International Classification of Disease 9th revision (ICD-9) codes.
Logistics regression analysis was used to estimate the adjusted odds ratio (aOR) of outcomes amongst participants with coexisting NASH/HIV while accounting for comorbidities and this was compared to those with NASH alone.
RESULTS:
The mean age sample was 49 ± 12 (61% female, 39% male).
The rates of ascites were higher among those with NASH/HIV compared to NASH alone (10.
1% vs 4.
6%, P < 0.
005).
After adjusting for comorbidities, the aOR for hepatic encephalopathy 1.
232 (0.
379-4.
009), ascites 1.
753 (0.
962-3.
196) and portal hypertension 2.
258 (0.
276-18.
465) was higher in NASH/HIV group compared to NASH alone.
Stratified analysis based on age and sex revealed that females with NASH/HIV have a statistically significant higher odd for ascites; age 18-45, aoR 4.
752 (2.
155-10.
478) and portal hypertension age 46- 75 aoR 19.
832 (1.
182 - 332.
644) compared with NASH alone.
CONCLUSION:
African American female patients with NASH coexisting with HIV were at a higher risk for portal hypertension and ascites when compared to those with NASH alone.
Further studies will look to evaluate and mitigate the impact of HIV on NASH in this patient population.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Interactions Between Human Immunodeficiency Virus–1, Hepatitis Delta Virus and Hepatitis B Virus Infections in 260 Chronic Carriers of Hepatitis B Virus
Interactions Between Human Immunodeficiency Virus–1, Hepatitis Delta Virus and Hepatitis B Virus Infections in 260 Chronic Carriers of Hepatitis B Virus
To evaluate the factors determining the severity of chronic hepatitis B virus infection and the interactions of human immunodeficiency virus and hepatitis delta virus infections, w...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
PREVALENCE OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS IN INJECTION DRUG USERS OF KHYBER PAKHTUNKHWA, AND FACTORS AFFECTING ITS OCCURRENCE
PREVALENCE OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS IN INJECTION DRUG USERS OF KHYBER PAKHTUNKHWA, AND FACTORS AFFECTING ITS OCCURRENCE
Objective: Our main objective was to find out the prevalence of Hepatitis C virus and Human immunodeficiency virus and its co presence in injection drug users. We have to show the ...

